ATE383859T1 - Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779 - Google Patents

Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779

Info

Publication number
ATE383859T1
ATE383859T1 AT04814371T AT04814371T ATE383859T1 AT E383859 T1 ATE383859 T1 AT E383859T1 AT 04814371 T AT04814371 T AT 04814371T AT 04814371 T AT04814371 T AT 04814371T AT E383859 T1 ATE383859 T1 AT E383859T1
Authority
AT
Austria
Prior art keywords
compressable
cci
direct
pharmaceutical composition
oral administration
Prior art date
Application number
AT04814371T
Other languages
English (en)
Inventor
Muhammad Ashraf
Eric Benjamin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE383859T1 publication Critical patent/ATE383859T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04814371T 2004-01-08 2004-12-14 Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779 ATE383859T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08

Publications (1)

Publication Number Publication Date
ATE383859T1 true ATE383859T1 (de) 2008-02-15

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04814371T ATE383859T1 (de) 2004-01-08 2004-12-14 Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779

Country Status (30)

Country Link
US (1) US20050152983A1 (de)
EP (1) EP1701698B1 (de)
JP (1) JP2007517879A (de)
KR (1) KR20060130162A (de)
CN (1) CN1921861A (de)
AR (1) AR047180A1 (de)
AT (1) ATE383859T1 (de)
AU (1) AU2004314213A1 (de)
BR (1) BRPI0418373A (de)
CA (1) CA2552595A1 (de)
CR (1) CR8491A (de)
CY (1) CY1107373T1 (de)
DE (1) DE602004011398T2 (de)
DK (1) DK1701698T3 (de)
EC (1) ECSP066757A (de)
ES (1) ES2298861T3 (de)
GT (1) GT200500003A (de)
HN (1) HN2005000005A (de)
IL (1) IL176519A0 (de)
MX (1) MXPA06007829A (de)
NO (1) NO20062930L (de)
PA (1) PA8621201A1 (de)
PE (1) PE20050683A1 (de)
PL (1) PL1701698T3 (de)
PT (1) PT1701698E (de)
RU (1) RU2006122517A (de)
TW (1) TW200526213A (de)
UA (1) UA84903C2 (de)
WO (1) WO2005070393A2 (de)
ZA (1) ZA200605631B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84881C2 (ru) 2003-09-03 2008-12-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
JP4224115B2 (ja) * 2004-04-14 2009-02-12 ワイス ラパマイシン４２−エステル誘導体の位置特異的合成
CN1946852A (zh) * 2004-04-27 2007-04-11 惠氏公司 利用雷帕霉素特异性甲基化酶标记雷帕霉素
WO2006089312A2 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
WO2007059106A2 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
JP5475443B2 (ja) * 2006-06-28 2014-04-16 エミスフェアー・テクノロジーズ・インク 硝酸ガリウム製剤
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
JP6793652B2 (ja) * 2015-09-03 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
AU2003272489B2 (en) * 2002-09-17 2008-11-13 Wyeth Granulated formulation of the rapamycin ester CCI779
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060052880A (ko) * 2003-07-25 2006-05-19 와이어쓰 동결건조된 ｃｃｉ- 779 제형
JP4227649B2 (ja) * 2003-08-07 2009-02-18 ワイス Ｃｃｉ−７７９の位置選択的合成
UA84881C2 (ru) * 2003-09-03 2008-12-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
WO2006089312A2 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations

Also Published As

Publication number Publication date
DE602004011398T2 (de) 2009-01-15
US20050152983A1 (en) 2005-07-14
AR047180A1 (es) 2006-01-11
PA8621201A1 (es) 2005-12-23
DE602004011398D1 (de) 2008-03-06
GT200500003A (es) 2005-08-18
CN1921861A (zh) 2007-02-28
WO2005070393A2 (en) 2005-08-04
EP1701698B1 (de) 2008-01-16
IL176519A0 (en) 2006-10-05
UA84903C2 (ru) 2008-12-10
CA2552595A1 (en) 2005-08-04
PE20050683A1 (es) 2005-11-04
DK1701698T3 (da) 2008-05-05
PL1701698T3 (pl) 2008-03-31
ES2298861T3 (es) 2008-05-16
HN2005000005A (es) 2009-04-17
ZA200605631B (en) 2010-01-27
MXPA06007829A (es) 2006-09-01
NO20062930L (no) 2006-10-02
ECSP066757A (es) 2006-11-16
JP2007517879A (ja) 2007-07-05
RU2006122517A (ru) 2008-02-20
EP1701698A2 (de) 2006-09-20
CY1107373T1 (el) 2012-12-19
PT1701698E (pt) 2008-03-27
KR20060130162A (ko) 2006-12-18
AU2004314213A1 (en) 2005-08-04
BRPI0418373A (pt) 2007-05-22
WO2005070393A3 (en) 2006-09-28
CR8491A (es) 2008-08-21
TW200526213A (en) 2005-08-16
HK1090308A1 (en) 2006-12-22

Similar Documents

Publication Publication Date Title
ATE383859T1 (de) Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
EP1750674A4 (de) Mikropartikel für die orale abgabe
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
BRPI0511900A (pt) composições farmacêuticas
RS20120139A3 (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
EP2152195A4 (de) Peptidarzneimittel für orale abgabe
DK2172205T3 (da) Farmaceutisk formulering bestående af lanthan-forbindelser
NO20043367L (no) Oralt farmasoytisk preparat
SK4326U (sk) Farmaceutická kompozícia s predĺženým uvoľňovaním
DK1587478T3 (da) Farmaceutisk sammensætning
EP1750677A4 (de) Abgabesystem für eine orale therapeutische verbindung
SK4325U (sk) Farmaceutická kompozícia s postupným uvoľňovaním
DE60317803D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
EP1954298A4 (de) Abgabesystem für eine orale therapeutische verbindung
ATE474561T1 (de) Orodispersible pharmazeutische zusammensetzung für die orale, oromukosale oder sublinguale verabreichung von agomelatin
EA200401515A1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
DK1837019T3 (da) Orale dispergerbare farmaceutiske sammensætninger
ATE374172T1 (de) Hexensäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon
DE602004012413D1 (de) Halbfeste formulierung für die orale verabreichung des taxols
ATE455540T1 (de) Orale dosierform für die kontrollierte arzneimittelfreisetzung
ATE503749T1 (de) Buttersäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon
EP1581196A4 (de) Säurelabile arzneimittelzusammensetzungen
DE602005003907D1 (de) Benzothiadiazinderivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
DE602004020797D1 (de) Pharmazeutische zusammensetzung für die orale verabreichung eines pyrazol-3-carbonsäurederivats

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1701698

Country of ref document: EP

REN Ceased due to non-payment of the annual fee